Arrowstreet Capital’s Tvardi Therapeutics TVRD Stock Holding History

Arrowstreet Capital’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,553	Closed	-$566K	–	1455
2023 Q2	$566K	Buy	+5,553	New	+$765K	﹤0.01%	1056
2021 Q1	–	Sell	-772	Closed	-$421K	–	2587
2020 Q4	$421K	Sell	772 -150	-16%	-$78.6K	﹤0.01%	2048
2020 Q3	$422K	Buy	+922	New	+$536K	﹤0.01%	2062
2020 Q1	–	Sell	-2,006	Closed	-$1.16M	–	2165
2019 Q4	$1.16M	Buy	+2,006	New	+$1.41M	﹤0.01%	1297
2019 Q2	–	Sell	-608	Closed	-$430K	–	1761
2019 Q1	$430K	Buy	+608	New	+$364K	﹤0.01%	1529

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Arrowstreet Capital's TVRD Position: Q3 2023 in Review

Arrowstreet Capital sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 5,553 shares — an estimated $566K sold.

Arrowstreet Capital first reported a position in TVRD in Q1 2019 and held it in 5 quarters. The position peaked at $1.16M in Q4 2019. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

Arrowstreet Capital reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
Arrowstreet Capital sold 5,553 Tvardi Therapeutics shares in Q3 2023, an estimated $566K.
Arrowstreet Capital first reported a position in Tvardi Therapeutics in Q1 2019 and held it in 5 quarters.
Arrowstreet Capital's Tvardi Therapeutics position peaked at $1.16M in Q4 2019.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Arrowstreet Capital's 13F filing for Q3 2023, filed 14 Nov 2023.